Immunoassay Control Monitors 54 Analytes Including Vitamin D
|
By LabMedica International staff writers Posted on 03 Jan 2012 |
An immunoassay premium plus control is designed to monitor the accuracy and precision of up to 54 analytes including 25-OH Vitamin D and 1-25(OH)2 Vitamin D.
Specific target values are also provided for a wide range of fertility hormones, thyroid hormones, steroid hormones, kidney function tests, therapeutic drugs, and tumor markers. The inclusion of routinely run tumor markers and parameters such as intact parathyroid hormone (PTH) allows quality control practices to be simplified by dramatically reducing the number of controls used in the laboratory with the added benefit of cost and time savings.
The Acusera immunoassay premium plus control is being offered by Randox (Crumlin, United Kingdom). It has a shelf life of up to four years and is suitable for long-term quality control (QC) monitoring. It can significantly reduce the costs and problems associated with changing lot numbers.
In addition to low Vitamin B12 levels, the Randox Immunoassay Premium and Premium Plus controls contain ultra low levels of ferritin and thyroid stimulating hormone (TSH) as well as other vitamins. The control also contains many of the routinely run tumor markers including alpha-fetoprotein (AFP), CA15-3, CA19-9, CA-125, CEA, prostate specific antigen (PSA), and Free-PSA.
Vitamin D can also be found in the Randox RIQAS Immunoassay EQA program. RIQAS (Randox International Quality Assessment Scheme) is a large global EQA scheme with more than 20,000 participants in over 100 countries worldwide.
Related Links:
Randox
Specific target values are also provided for a wide range of fertility hormones, thyroid hormones, steroid hormones, kidney function tests, therapeutic drugs, and tumor markers. The inclusion of routinely run tumor markers and parameters such as intact parathyroid hormone (PTH) allows quality control practices to be simplified by dramatically reducing the number of controls used in the laboratory with the added benefit of cost and time savings.
The Acusera immunoassay premium plus control is being offered by Randox (Crumlin, United Kingdom). It has a shelf life of up to four years and is suitable for long-term quality control (QC) monitoring. It can significantly reduce the costs and problems associated with changing lot numbers.
In addition to low Vitamin B12 levels, the Randox Immunoassay Premium and Premium Plus controls contain ultra low levels of ferritin and thyroid stimulating hormone (TSH) as well as other vitamins. The control also contains many of the routinely run tumor markers including alpha-fetoprotein (AFP), CA15-3, CA19-9, CA-125, CEA, prostate specific antigen (PSA), and Free-PSA.
Vitamin D can also be found in the Randox RIQAS Immunoassay EQA program. RIQAS (Randox International Quality Assessment Scheme) is a large global EQA scheme with more than 20,000 participants in over 100 countries worldwide.
Related Links:
Randox
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
Lung cancer care increasingly relies on biomarker-guided patient stratification, but tissue biopsy can be impractical and treatment selection remains difficult for many patients. Blood-based assays that... Read more
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








